As we count down to our 15th anniversary, each month we reflect on some of our favourite 15 things.
Here are 15 memorable landmarks that we are proud to look back on.
As we count down to our 15th anniversary, each month we reflect on some of our favourite 15 things.
Here are 15 memorable landmarks that we are proud to look back on.
1999
MMV is officially launched on 3 November under the umbrella of the WHO Special Program for Research and Training in Tropical Diseases (TDR). MMV adopts the mission to Discover and Develop new effective and affordable antimalarials.
2000
MMV establishes its first alliance with industry (Glaxo Wellcome) and academia (University of Bristol and London School of Hygiene and Tropical Medicine) to work on the enzyme lactate dehydrogenase. This new alliance is a huge turning point for MMV – opening up a new world of possibilities through access to the pharmaceutical industry’s chemical and natural product libraries. Moreover, it lays the foundation for fruitful relationships with Pharma in the future.
2001
MMV discusses the idea of a novel concept – the mini-portfolio – with legal counsel (Stephen Whybrow, of Cameron McKenna). The mini-portfolio will allow the efficient distribution of resources within a group of discovery projects held by MMV and an industrial partner.
2002
TDR, MMV and Shin Poong Pharmaceutical, Co. Ltd. sign an agreement to develop Pyronaridine-Artesunate (Pyramax®), just as the potential combination therapy embarks on preclinical development.
2003
MMV and Novartis sign an agreement to make a paediatric formulation of Coartem® (Artemether-Lumefantrine) –Coartem® Dispersible.
2004
MMV joins hands with Sigma-Tau Industrie Farmaceutiche Reunite, Oxford University and Holley Pharmaceutical Co. Inc. to develop a high quality medicine to treat uncomplicated malaria – Dihdroartemisinin-Piperaquine (Eurartesim®).
2005
A Burkina Faso clinical trial site is the first to enroll a patient for a clinical development project and the first to receive MMV support for capacity building.
2006
The newly created Access and Delivery department transforms MMV into a 3D organization – Discover, Develop, Deliver. The Access and Delivery Advisory Committee (ADAC) is established.*
* This department was later renamed Access & Product Management, and ADAC became APMAC.
2007
The regulatory dossier for Coartem® Dispersible is submitted to Swissmedic.
2008
Coartem® Dispersible is approved by Swissmedic – a stringent regulatory authority.
2009
Coartem® Dispersible is launched in three African countries as well as Switzerland. The regulatory dossier for Eurartesim®is submitted to EMEA, the European stringent regulatory authority.
2010
Guilin’s artesunate for injection receives WHO prequalification. MMV worked with Guilin Pharmaceutical and helped it become the first company to receive WHO prequalification for its injectable artesunate – the gold standard treatment for severe malaria – allowing it to be purchased with donor funds and thus reach more of the patients who need it.
2011
Eurartesim® developed in partnership with Sigma-Tau receives EMA approval and less than three years after launch, deliveries of Coartem® Dispersible reach the 100 million mark.
2012
Pyramax® developed in partnership with Shin Poong is granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58 and the WHO prequalification programme adds Pyramax to its list of approved medicines.
2013
200 million treatments of Coartem® Dispersible are dispatched to 50 malaria-endemic countries. 12 million vials of injectable artesunate are delivered to treat severe malaria, saving approximately 80,000 - 90,000 additional young lives compared to treatment with quinine.
Slideshow created April 2014
Photo Credits: Slide 1 - Samson Olajide Banjo, Slide 2 - Anna Wang, Slide 3 - BMC St Jude, Slide 4 - Anna Wang, Slide 5 - MMV, Slide 6 - MMV, Slide 7 - Anna Wang, Slide 8 - Anna Wang, Slide 9 - Anna Wang, Slide 10 - MMV, Slide 11 - MMV, Slide 12 - MMV, Slide 13 - MMV, Slide 14 - MMV, Slide 15 - Novartis.